53 patents
Utility
ANTI-PD-L1 Antibodies
4 Jan 24
Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.
Bruce KEYT, Leonard George PRESTA, Ramesh BALIGA
Filed: 7 Sep 23
Utility
Uses of Effector Cell Engaging Molecules with Moieties of Differing Potencies
4 Jan 24
This disclosure provides methods of treating cancer comprising administering effector cell engaging molecules comprising one or more tumor targeting moieties and one or more effector cell engaging moieties.
Daniel S. CHEN, Wayne R. GODFREY, Maria Genevive Hermoso HERNANDEZ, Iris SISON, Ibrahim QAZI, Kevin Charles HART, Maya Fay KOTTURI
Filed: 17 Nov 21
Utility
Modified J-chain
7 Sep 23
The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Bruce KEYT, Leonard George PRESTA, Fen ZHANG, Ramesh BALIGA
Filed: 3 Nov 22
Utility
PD-1 Agonist Multimeric Binding Molecules
6 Jul 23
This disclosure provides multimeric binding molecules that specifically and agonistically bind to programmed cell death protein 1 (PD-1).
Bruce KEYT, Todd METZGER, Angus SINCLAIR
Filed: 21 Apr 21
Utility
Immunostimulatory Multimeric Binding Molecules
29 Jun 23
This disclosure provides multivalent binding molecule comprising a modified J-chain that comprises an immune stimulatory agent.
Ramesh BALIGA, Thierry GIFFON, Dean NG
Filed: 14 Aug 20
Utility
Tumor Necrosis Factor (TNF) Superfamily Receptor Igm Antibodies and Uses Thereof
29 Jun 23
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Beatrice WANG, Max Allen SCHWARZER, Bruce Alan KEYT, Ramesh BALIGA
Filed: 14 Nov 22
Utility
Binding Molecules with Modified J-chain
29 Jun 23
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
Bruce A. KEYT, Leonard G. PRESTA, Ramesh BALIGA
Filed: 11 Nov 22
Utility
Binding molecules with modified J-chain
2 May 23
The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Filed: 30 Sep 16
Utility
Highly Sialylated Multimeric Binding Molecules
9 Mar 23
This disclosure provides a monoclonal population of highly sialylated multimeric binding molecules where the population includes IgM antibodies, IgM-like antibodies, or other IgM-derived binding molecules, where the population of binding molecules has a higher level of sialic acid content than is found in normal serum IgM.
Bruce KEYT, Ramesh BALIGA, Sachi AHMED, Kevin CARLIN, Paul HINTON, Mark SMITH, Avneesh SAINI, Huyen TRAN, Marvin PETERSON
Filed: 5 Jan 21
Utility
Multimeric Coronavirus Binding Molecules and Uses Thereof
23 Feb 23
This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2.
Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
Filed: 27 Jul 21
Utility
Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
14 Feb 23
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Beatrice Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
Filed: 28 Apr 20
Utility
Modified J-chain
17 Jan 23
The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
Filed: 19 Sep 18
Utility
Binding molecules with modified J-chain
3 Jan 23
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Filed: 16 Jan 20
Utility
Multi-valent hepatitis B virus antigen binding molecules and uses thereof
27 Dec 22
This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain.
Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
Filed: 19 Feb 20
Utility
Multimeric Coronavirus Binding Molecules and Uses Thereof
22 Dec 22
This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2.
Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
Filed: 14 Jul 22
Utility
Multimeric Antibodies with Enhanced Selectivity for Cells with High Target Density
24 Nov 22
This disclosure provides a multimeric binding molecule, e.g., an IgM, IgM-like, IgA, or IgA-like binding molecule, e.g., an antibody with enhanced selectivity for cells expressing a target antigen at high density, e.g., tumor cells.
Ramesh BALIGA, Paul HINTON, Bruce KEYT
Filed: 18 Sep 20
Utility
Modified Human Igm Constant Regions for Modulation of Complement-dependent Cytolysis Effector Function
27 Oct 22
The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the Cμ3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.
Ramesh BALIGA, Dean NG
Filed: 10 Jun 22
Utility
Igm Glycovariants
29 Sep 22
This disclosure provides an isolated IgM-derived binding molecule, e.g., an IgM antibody, IgM-like antibody, or other IgM-derived binding molecule, including at least one variant IgM-derived heavy chain, where the at least one variant IgM-derived heavy chain includes a variant IgM heavy chain constant region associated with a binding domain that specifically binds to a target, where at least one asparagine (N)-linked glycosylation motif of the variant IgM heavy chain constant region is mutated to prevent glycosylation at that motif, and/or at least one N-linked glycosylation motif is introduced into the variant IgM heavy chain.
Bruce KEYT, Dean NG, Ramesh BALIGA
Filed: 21 Aug 20
Utility
Multimeric Bispecific ANTI-CD123 Binding Molecules and Uses Thereof
15 Sep 22
This disclosure provides multivalent, bispecific, anti-CD123 binding molecule comprising a modified J-chain that specifically binds to an immune effector cell.
Manal AMOURY, Angus SINCLAIR, Bruce KEYT
Filed: 14 Aug 20
Utility
Multimeric SARS-COV-2 Binding Molecules and Uses Thereof
25 Aug 22
This disclosure provides multimeric binding molecules that bind to SARS-CoV-2.
Zhiqiang KU, Xuping XIE, Paul HINTON, Ningyan ZHANG, Bruce KEYT, Dean NG, Stephen CARROLL, Pei-Yong SHI, Zhiqiang AN
Filed: 15 Feb 22